Publications by authors named "T Pertynski"
Non-hormonal pharmacological interventions for managing vasomotor symptoms-how can we help: 2024 landscape.
Eur J Obstet Gynecol Reprod Biol
November 2024
Article Synopsis
- Vasomotor symptoms (VMS), such as hot flashes, affect about 70% of menopausal women, with 25% experiencing them severely; these symptoms are linked to changes in hypothalamic neurotransmitters rather than just estrogen withdrawal.* -
- The review aims to identify non-hormonal pharmacological treatments for VMS, especially for women who cannot or prefer not to use hormone therapy.* -
- Fezolinetant, a newly developed NK3R antagonist, represents a promising non-hormonal option for effectively managing these symptoms, expanding the range of available treatments for healthcare providers in 2024.*
Premenopausal and postmenopausal women during the COVID-19 pandemic.
Prz Menopauzalny
September 2022
The current global COVID-19 mortality rate is estimated to be around 3.4%; however, it is dependent on age, sex, and comorbidities. Epidemiological evidence shows gender disparities in COVID-19 severity and fatality, with non-menopausal females having milder severity and better outcomes than age-matched males.
View Article and Find Full Text PDFMenopause is one of the most important events in the female reproductive life cycle, being a transition from the reproductive to the nonreproductive stage. It is a milestone that may have a negative influence on quality of life and one that brings in several physiological changes that affect the life of a woman permanently. According to a Polish epidemiological forecast, in 2050 the average female life expectancy will be 87.
View Article and Find Full Text PDFArticle Synopsis
- - Metabolic disorders such as dyslipidemia and insulin resistance that occur during menopause increase the risk of cardiovascular disease in women and are linked to issues like obesity and inflammation.
- - Early diagnosis and treatment of these disorders are crucial for improving women's quality and length of life, with a focus on prevention as a key goal for healthcare providers.
- - While menopausal hormone therapy (HT), especially estrogen therapy, might be considered in specific cases, lifestyle changes like a healthy diet and moderate exercise are the primary recommended strategies for addressing menopausal metabolic issues.
Effect of transdermal hormone therapy on platelet haemostasis in menopausal women.
Ann Agric Environ Med
December 2015
Introduction: Despite the undeniably positive effect on the quality of life of menopausal women, menopausal hormone therapy (HT) also has negative side-effects, which include, among others, thromboembolic complications.
Objective: To assess the effect of a popular type of this therapy - transdermal HT on platelet hemostasis, which plays a significant role in intravascular coagulation.
Materials And Method: The study group consisted of 92 postmenopausal women: 1) group G1 (n=30), treated with transdermal HT (17β-estradiol 50 μg/day plus NETA 170 μg/day); 2) group G2 (n=31), treated with the above transdermal HT and low dosage of acetylsalicylic acid (ASA); 3) control group P (n=31).